How startup funding works?

Startup funding is the process of getting money to build and grow a company, usually by exchanging a portion of ownership (equity) or a promise of future equity for cash. The key idea: you don’t raise money “because you can”—you raise to reach a specific milestone that makes the company meaningfully more valuable and less risky.

If you’re a technical/medical/scientific founder, think of funding like staged clinical development: each round is meant to “de-risk” the next step with evidence (traction, product, revenue, regulatory progress, etc.).

1) The core mechanics: you trade risk for capital

Investors fund startups because they expect the company’s value to increase. They accept high risk in exchange for a chance at high returns. Founders accept dilution (owning a smaller percentage) in exchange for speed and a higher chance of winning.

Three terms you’ll see constantly:

• Valuation: what the company is worth for the purpose of the round. Early valuations are more art than science.
• Dilution: the percentage of the company you give up when new shares are issued. If you own 100% and sell 20% in a round, you now own 80% (before future rounds).
• Runway: how long your cash lasts at your current burn (spend rate). Runway = cash / monthly burn.

Most rounds are designed to buy 12–24 months of runway, enough time to hit the next milestone and raise again (or become self-sustaining).

2) The typical funding stages (and what “progress” means)

Funding is usually described in stages. The names vary, but the logic is consistent: each stage expects stronger proof.

Bootstrapping (no outside investors)

You fund the business with savings, revenue, consulting, or grants (where applicable). Pros: no dilution, more control. Cons: slower, more personal risk.

Pre-seed

Goal: prove the problem and your ability to build a solution. Evidence might include customer interviews, a prototype, early pilots, or letters of intent (LOIs). Typical investors: angels (individuals) and small pre-seed funds.

Seed

Goal: prove early product-market fit (PMF)—meaning a real group of customers consistently wants and uses/buys the product. Evidence: retention, usage, paid pilots, early revenue, or strong pipeline. Typical investors: seed venture capital (VC) funds, larger angel syndicates.

Series A

Goal: prove a repeatable growth model. Investors look for a “machine” that turns spend into growth: predictable acquisition channels, improving unit economics, and a team that can scale execution.

Series B and beyond

Goal: scale aggressively—new markets, larger sales teams, international expansion, acquisitions, etc. Expectations: strong revenue growth, robust metrics, and operational maturity.

Note: In deep tech and medtech, milestones may include technical validation, clinical evidence, regulatory strategy progress, and reimbursement planning. The stage labels still apply, but “traction” may look different than in a pure software startup.

3) Common funding instruments: priced rounds vs. SAFEs/notes

There are two main ways early-stage funding is structured:

A) Priced equity round

You set a valuation now, and investors buy shares at that price. This is common at Seed and later, sometimes at Pre-seed.

Key terms:

• Pre-money valuation: value before the new money comes in.
• Post-money valuation: pre-money + amount raised.

Example: If you raise $2M at a $8M pre-money valuation, post-money is $10M. Investors own $2M/$10M = 20% post-round (ignoring option pool adjustments for simplicity).

B) SAFE or convertible note (convertible instruments)

A SAFE (Simple Agreement for Future Equity) and a convertible note are ways to raise now without setting a valuation today. The money converts into equity in a future priced round.

Common conversion terms:

• Valuation cap: the maximum valuation at which the investor’s money converts (good for the investor if you do very well).
• Discount: e.g., 20% discount to the next round’s price.
• Interest (notes only): notes are debt until conversion; SAFEs are not debt.

SAFEs are popular because they’re simpler and faster, but they can create “hidden dilution” if you stack multiple SAFEs without tracking the eventual ownership impact.

4) How investors decide: traction, team, market, and economics

Investors usually underwrite (evaluate) four buckets:

• Market: Is the opportunity big enough? “Big” depends on business model, but VCs generally want outcomes that can return the fund.
• Problem & solution: Is the pain acute and frequent? Is your solution meaningfully better (10x) or uniquely positioned?
• Team: Do you have the technical ability and the commercial plan? For first-time founders, investors look for coachability and speed of learning.
• Traction & unit economics: Evidence that customers want it and the business can work financially.

Two pieces of jargon worth translating:

Unit economics = the profitability of one “unit” of your business (one customer, one order, one device). Common metrics include:

• CAC (Customer Acquisition Cost): what it costs to acquire a customer.
• LTV (Lifetime Value): gross profit you expect from a customer over time.
• Gross margin: (revenue − cost of delivering the product) / revenue.

Early on, these numbers can be rough. What matters is whether you have a credible path to healthy economics as you scale.

5) Term sheets, control, and the dilution you should actually worry about

A term sheet is a non-binding document (mostly) that outlines the key terms of an investment before final legal docs. It’s where many founder-friendly vs. founder-hostile outcomes are set.

Important term sheet concepts:

• Board control: Who sits on the board and who can outvote whom. Losing control too early can backfire.
• Liquidation preference: Who gets paid first if the company is sold. A common structure is “1x non-participating,” meaning investors get their money back first (up to 1x) or convert to equity—whichever is better. More aggressive preferences can heavily reduce founder outcomes.
• Option pool: shares reserved for future employees. Often negotiated and can effectively increase dilution if added pre-money.
• Pro-rata rights: investor’s right to maintain ownership in future rounds.

Practical dilution guidance: Many startups target giving up roughly 10–25% per priced round (varies widely). The “right” amount depends on how much you need to hit the next milestone and the valuation you can justify.

What you should worry about more than dilution is raising without a milestone plan. If you raise and then miss the milestone, the next round can become a down round (raising at a lower valuation), which is painful for morale, hiring, and ownership.

6) A simple way to decide how much to raise

Use a milestone-driven budget:

1. Define the next value-inflection milestone (e.g., “10 paying customers,” “regulatory pathway validated,” “clinical pilot completed,” “$50k MRR,” “hardware v2 passes reliability testing”).
2. List the work required: hires, contractors, cloud costs, lab work, compliance, sales efforts.
3. Estimate monthly burn after the round.
4. Choose runway: typically 18 months + a buffer (fundraising can take 3–6+ months).
5. Add a contingency (often 10–20%) because plans slip.

Then sanity-check: does this raise size match what your stage can realistically attract? If not, reduce scope, find non-dilutive funding (where relevant), or adjust milestones.

What to do next

1. Map your stage and milestone: write a one-sentence “next round milestone” and the evidence you’ll show investors.
2. Build a 12–24 month cash plan: estimate burn, runway, and how much you need to raise; stress-test with a slower-sales scenario. Use /finances.
3. Simulate dilution: model a SAFE stack vs. a priced round and see founder ownership after 2–3 rounds. Try /Simulator.
4. Pressure-test your pitch: get feedback on clarity, milestones, and investor fit using /roast (or compare versions via /roast-battle).
5. Study your competitive landscape: write a simple competitor table (who, wedge, pricing, distribution) before you talk to investors. Use /Competitor_study.